Does Rallies show 13F holders for ACAD?

Yes. Rallies tracks hedge fund and 13F ownership data for ACAD, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ACAD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ACAD. It does not provide personalized investment advice.

ACAD (Acadia Pharmaceuticals Inc.) Stock Analysis - Hedge Fund Holdings

Acadia Pharmaceuticals Inc. (ACAD) is a publicly traded Healthcare sector company. As of May 21, 2026, ACAD trades at $20.95 with a market cap of $3.54B and a P/E ratio of 9.34. ACAD moved +2.25% today. Year to date, ACAD is -19.89%; over the trailing twelve months it is -3.41%. Its 52-week range spans $13.40 to $28.35. Analyst consensus is strong buy with an average price target of $32.77. Rallies surfaces ACAD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ACAD stock?

Hedge funds tracked by Rallies that own ACAD include Orbimed Advisors, Panagora Asset, Bridgewater Associates, Eisler Capital, and Centerbook Partners. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Acadia Pharmaceuticals Inc..

ACAD Key Metrics

Key financial metrics for ACAD
Metric	Value
Price	$20.95
Market Cap	$3.54B
P/E Ratio	9.34
EPS	$2.23
Dividend Yield	0.00%
52-Week High	$28.35
52-Week Low	$13.40
Volume	0
Avg Volume	0
Revenue (TTM)	$1.10B
Net Income	$375.65M
Gross Margin	91.47%

Top Hedge Funds Holding ACAD

Orbimed Advisors holds 764.60K shares of ACAD, changed +0.00% as of Sep 30, 2024.
Panagora Asset holds 688.65K shares of ACAD, changed +1.11% as of Mar 31, 2026.
Bridgewater Associates holds 141.81K shares of ACAD, changed +2.63% as of Mar 31, 2026.
Eisler Capital holds 50.34K shares of ACAD, changed +27.94% as of Jun 30, 2024.
Centerbook Partners holds 19.74K shares of ACAD, changed +76.97% as of Mar 31, 2026.

Latest ACAD News

Acadia Q1 EPS $0.02, $268.1M Revenue Miss, $1.22B–$1.28B Outlook — May 6, 2026
Acadia Pharmaceuticals Upgraded to Buy After 25% Pullback, Maintains $29 Target — Mar 25, 2026
EU Rejects Trofinetide for Rett Syndrome, Acadia Plans Re-Examination — Mar 5, 2026
ACADIA Q4 Sales Surge to $284M, Guides $1.22–1.28B 2026 Revenue, Wolfe Sets $33 Target — Mar 2, 2026
Acadia Posts Record Q4 Revenue Growth, Announces Phase III Pipeline Starts — Feb 26, 2026

Recent ACAD Insider Trades

Kihara James sold 1.33K (~$29.02K) on May 4, 2026.
Schneyer Mark C. sold 3.51K (~$76.40K) on May 4, 2026.
Schneyer Mark C. sold 2.71K (~$60.14K) on Apr 7, 2026.

ACAD Analyst Consensus

15 analysts cover ACAD: 0 strong buy, 12 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.77.

Common questions about ACAD

Who owns ACAD stock?: Hedge funds tracked by Rallies that own ACAD include Orbimed Advisors, Panagora Asset, Bridgewater Associates, Eisler Capital, and Centerbook Partners. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Acadia Pharmaceuticals Inc..
Does Rallies show 13F holders for ACAD?: Yes. Rallies tracks hedge fund and 13F ownership data for ACAD, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ACAD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ACAD. It does not provide personalized investment advice.